Advanced search
Advanced search
Advanced search
Advanced search
Advanced search
Is investment in personalized medicine worthwhile?
Nowakowska, Elżbieta ; Metelska, Jana ; Matschay, Arleta ; Burda, Kinga ; Czubak, Anna ; Kus, Krzysztof
Committee on Biotechnology PAS ; Institute of Bioorganic Chemistry PAS
Monografia opublikowana w zeszycie Biotechnologia 2(85)'2009
Since the dawn of the 21st century, pharmacology has become a field increasingly closely related to the development of a new science - genomics. Due to increasingly smaller efficacy of using “conventional” therapies, the world of science is starting to seek drugs dedicated to patients with a specific genotype. The possibility of finding the genetic background of diseases largely incurable to this date, such as cancers, diabetes or depression, will allow for “targeted therapy”, improving thereby therapy efficacy by adjusting optimum treatment agents to the individual genetic profile of a specific patient. With propagation of this new type of medicine - personalized medicine, the approach to therapy and the attitude of the patient himself are changing, as the patient seeing efficacy of his therapy is more willing to closely cooperate with the managing physician. Considerations discussed therein allow for a conclusion that further pharmacogenetic research is necessary not only to improve therapy efficacy, but also to seek possibilities of reasonable cost savings in medicine.
0860-7796 ; oai:rcin.org.pl:72687 ; IChB B-80
Library of Institute of Bioorganic Chemistry PAS
Creative Commons Attribution BY-SA 4.0 license
Institute of Bioorganic Chemistry of the Polish Academy of Science
Institute of Bioorganic Chemistry of the Polish Academy of Science
Oct 2, 2020
Jun 12, 2019
158
https://rcin.org.pl./publication/94568
Edition name | Date |
---|---|
Czy warto inwestować w medycynę personalizowaną? | Oct 2, 2020 |
Borkowska, Bożenna
Ziółkowski, Piotr Babula- Skowrońska, Danuta Kaczmarek, Małgorzata Cieśla, Agata Sadowski, Jan
Kaliszan, Roman Długokęcka, Justyna